Allelic frequency of PON1 Q192R, CYP2C19*2 and CYP2C19*17 among Jordanian patients taking clopidogrel

被引:5
作者
Rjoub, Malek [1 ]
Saleh, Akram [2 ]
Hakooz, Nancy [3 ]
Imraish, Amer [4 ]
Jarrar, Yazun [5 ]
Zihlif, Malek [1 ]
机构
[1] Univ Jordan, Fac Med, Dept Pharmacol, Amman, Jordan
[2] Univ Jordan, Dept Internal Med, Univ Jordan Hosp, Amman, Jordan
[3] Univ Jordan, Dept Biopharmaceut & Clin Pharm, Fac Pharm, Amman, Jordan
[4] Univ Jordan, Dept Biol, Fac Sci, Amman, Jordan
[5] AlZaytoonah Univ Jordan, Coll Pharm, Dept Pharm, Amman, Jordan
关键词
CYP2C9; polymorphisms; Clopidogrel; Genotype; Allele frequency; PON1; genes; GENETIC-POLYMORPHISM; GENOTYPE FREQUENCIES; CYP2C19; PHARMACOGENETICS; PARAOXONASE-1; PHENOTYPE; VARIANT; 2C19;
D O I
10.4314/tjpr.v17i11.24
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose: To investigate the influence of allelic frequencies of PON1 Q192R, CYP2C19*2 and CYP2C19*17 genetic polymorphisms on the response to clopidogrel among Jordanian patients. Methods: Polymorphisms in CYP2C19 were assessed among 148 patients using PCR-RFLP assay. Results: The CYP2C19*2, CYP2C19*17, and PON1 Q192R allele frequencies were 9.8, 28.72 and 28.7 %, respectively. On the genotyping side, the frequencies of CYP2C19*1/1* and CYP2C19*1/2* were 80.4 and 19.6 %, respectively, but none of the patients had CYP2C19*2/2* genotype. The genotype frequencies CYP2C19*17 were 47.97, 46.62 and 5.41 % for wild-type C-C, heterozygote C-T, and the mutant T-T, respectively. PON1 genotype was 42.7 % for QQ, and 57.8 % for QR. None of the patients had RR genotype. Conclusion: Relative to other populations, the observed allelic frequencies are consistent with the values reported for Caucasian and Middle Eastern populations.
引用
收藏
页码:2275 / 2280
页数:6
相关论文
共 25 条
  • [1] Distribution of CYP2C19*17 allele and genotypes in an Indian population
    Anichavezhi, D.
    Rao, U. S. Chakradhara
    Shewade, D. G.
    Krishnamoorthy, R.
    Adithan, C.
    [J]. JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 313 - 318
  • [2] Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population
    Aynacioglu, AS
    Sachse, C
    Bozkurt, A
    Kortunay, S
    Nacak, M
    Schröder, T
    Kayaalp, SO
    Roots, I
    Brockmöller, J
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 66 (02) : 185 - 192
  • [3] Paraoxonase-1 is a major determinant of clopidogrel efficacy
    Bouman, Heleen J.
    Schoemig, Edgar
    van Werkum, Jochem W.
    Velder, Janna
    Hackeng, Christian M.
    Hirschhaeuser, Christoph
    Waldmann, Christopher
    Schmalz, Hans-Guenther
    ten Berg, Jurrien M.
    Taubert, Dirk
    [J]. NATURE MEDICINE, 2011, 17 (01) : 110 - U287
  • [4] Camps J, 2011, NAT MED, V17, P1041, DOI 10.1038/nm.2386
  • [5] Genetic polymorphism analysis of CYP2C19 in Chinese Han populations from different geographic areas of mainland China
    Chen, Lingling
    Qin, Shengying
    Xie, Jing
    Tang, Jimin
    Yang, Lun
    Shen, Wen
    Zhao, Xinzhi
    Du, Jing
    He, Guang
    Feng, Guoyin
    He, Lin
    Xing, Qinghe
    [J]. PHARMACOGENOMICS, 2008, 9 (06) : 691 - 702
  • [6] Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study
    Collet, Jean-Philippe
    Hulot, Jean-Sebastien
    Pena, Anna
    Villard, Eric
    Esteve, Jean-Baptiste
    Silvain, Johanne
    Payot, Laurent
    Brugier, Delphine
    Cayla, Guillaume
    Beygui, Farzin
    Bensimon, Gilbert
    Funck-Brentano, Christian
    Montalescot, Gilles
    [J]. LANCET, 2009, 373 (9660) : 309 - 317
  • [7] Effect of cytochrome P450 polymorphisms on platelet reactivity after treatment with Clopidogrel in acute coronary syndrome
    Frere, Corinne
    Cuisset, Thomas
    Morange, Pierre-Emmanuel
    Qpilici, Jacques
    Camoin-Jaumd, Laurence
    Saut, Noemie
    Faille, Dorothee
    Lambert, Marc
    Juhan-Vague, Irene
    Bonnet, Jean-Louis
    Alessi, Marie-Christine
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2008, 101 (08) : 1088 - 1093
  • [8] Pharmacogenomic biomarker information in drug labels approved by the United States Food and Drug Administration: Prevalence of related drug use
    Frueh, Felix W.
    Amur, Shashi
    Mummaneni, Padmaja
    Epstein, Robert S.
    Aubert, Ronald E.
    DeLuca, Teresa M.
    Verbrugge, Robert R.
    Burckart, Gilbert J.
    Lesko, Lawrence J.
    [J]. PHARMACOTHERAPY, 2008, 28 (08): : 992 - 998
  • [9] CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation
    Geisler, Tobias
    Schaeffeler, Elke
    Dippon, Juergen
    Winter, Stefan
    Buse, Verena
    Bischofs, Christian
    Zuern, Christine
    Moerike, Klaus
    Gawaz, Meinrad
    Schwab, Matthias
    [J]. PHARMACOGENOMICS, 2008, 9 (09) : 1251 - 1259
  • [10] Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations
    Goldstein, JA
    Ishizaki, T
    Chiba, K
    deMorais, SMF
    Bell, D
    Krahn, PM
    Evans, DAP
    [J]. PHARMACOGENETICS, 1997, 7 (01): : 59 - 64